Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
Journal: Lancet (London, England)
Published: October 03, 2017
Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: August 06, 2013
N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
Journal: Arthritis and rheumatism
Published: May 03, 2012
Showing 1-3 of 3
Last Updated: 09/26/2026